Betul Oran, M.D.

Peer-Reviewed Articles

1. Popat UR, Saliba RM, Mehta RS, Chen J, Ganesh C, Woodworth G, McMullin B, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Jin Seon Im, Partow Kebriae, Issa F. Khouri, David Marin, Yago Nieto, Betul Oran B, Saini N, Srour SA, Rezvani K, Qalzibash M, Molldren JJ, Shpall EJ, Andersson BS and Champlin RE. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. BBMT 26(3, Supplement), 2020.
2. Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant 21(11):1948-54, 2015. e-Pub 2015. PMID: 26183077.
3. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica 100(10):1361-70, 2015. e-Pub 2015. PMID: 26250579.
4. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk 15(8):472-6, 2015. e-Pub 2015. PMID: 25963284.
5. Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1405-1412, 2015. e-Pub 2015. PMID: 25840338.
6. Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly RF, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant 21(7):1284-90, 2015. e-Pub 2015. PMID: 25708219.
7. Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 50(Supplement 2):S55-62, 2015. PMID: 26039209.
8. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase Ii Trial Of Gvhd Prophylaxis with Post-Transplantation Cyclophosphamide Following Reduced-Intensity Busulfan/Fludarabine (Bu/Flu) Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
9. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
10. Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SO. Can a Female Donor for a Male Recipient Decrease the Relapse Rate for Patients With Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation?. Biol Blood Marrow Transplant 21(4):713-9, 2015. e-Pub 2014. PMID: 25540936.
11. Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. Biol Blood Marrow Transplant 20(12):1975-81, 2014. e-Pub 2014. PMID: 25263628.
12. Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med 3(12):1435-43, 2014. e-Pub 2014. PMID: 25378655.
13. Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, Donor Type and use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(10):1618-25, 2014. e-Pub 2014. PMID: 24953017.
14. Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, Popat UR, Rondon G, Bassett RL, Gulbis A. BFR (bendamustine, fludarabine and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced risk of myelosuppression and severe graft-versus-host disease. Blood 124(14):2306-12, 2014. e-Pub 2014. PMID: 25145344.
15. Bear AS, Hanley PJ, Bosque DM, Cruz CR, Kaur I, Liu H, Kebriaei P, Hosing C, Rezvani K, Oran B, De Lima MJ, Bollard CM, Shpall EJ. Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy 16(8):1153-7, 2014. e-Pub 2014. PMID: 24582458.
16. Bejanyan N, Oran B, Shanley R, Warlick E, Ustun C, Vercellotti G, Verneris M, Wagner JE, Weisdorf D, Brunstein C. Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation. Bone Marrow Transplant 49(8):1029-35, 2014. e-Pub 2014. PMID: 24887379.
17. Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima M. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol 89(4):395-8, 2014. e-Pub 2014. PMID: 24375514.
18. Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, Litzow MR, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia 28(3):658-65, 2014. e-Pub 2013. PMID: 23989431.
19. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2014. e-Pub 2013. PMID: 24169268.
20. Ustun C, Wiseman AC, Defor TE, Yohe S, Linden MA, Oran B, Burke M, Warlick E, Miller JS, Weisdorf D. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplant 48(11):1415-20, 2013. e-Pub 2013. PMID: 23933764.
21. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 2013. e-Pub 2013. PMID: 23872222.
22. Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Oran B, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer 119(18):3318-25, 2013. e-Pub 2013. PMID: 23775587.
23. Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. Am J Hematol 88(3):198-200, 2013. e-Pub 2013. PMID: 23345254.
24. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 2013. e-Pub 2013. PMID: 23330820.
25. Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities at Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2013. e-Pub 2012. PMID: 22982533.
26. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. PMID: 23234514.
27. Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, Warlick ED, Wagner JE, Weisdorf DJ. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant 47(4):494-8, 2012. e-Pub 2011. PMID: 21602900.
28. Oran B, Wagner JE, DeFor TE, Weisdorf DJ, Brunstein CG. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant 17(9):1327-34, 2011. e-Pub 2011. PMID: 21232621.
29. Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas. Biol Blood Marrow Transplant 17(7):1025-32, 2011. e-Pub 2010. PMID: 21047561.
30. McCormack SE, Cao Q, Oran B, Weisdorf DJ, Warlick ED. Pre-transplant consolidation chemotherapy may not improve outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. Leuk Res 35(6):757-61, 2011. e-Pub 2011. PMID: 21232793.
31. Oran B, Dolan M, Cao Q, Brunstein C, Warlick E, Weisdorf D. Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia. Biol Blood Marrow Transplant 17(3):356-64, 2011. e-Pub 2010. PMID: 20553926.
32. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a 'melphalan recall' reaction. Bone Marrow Transplant 45(1):21-4, 2010. e-Pub 2009. PMID: 19421171.
33. van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, Giralt S. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 15(5):610-7, 2009. PMID: 19361753.
34. Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima M. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant 43(9):685-92, 2009. e-Pub 2008. PMID: 19011667.
35. Tam M, Seldin DC, Forbes BM, Connors LH, Skinner M, Oran B, Quillen K, Sanchorawala V. Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a case report with literature review. Amyloid 16(2):103-7, 2009. PMID: 20536404.
36. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 21(12):2540-4, 2007. e-Pub 2007. PMID: 17611563.
37. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-62, 2007. e-Pub 2007. PMID: 17382251.
38. Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA, Wei C, Anderlini P, Popat U, Shpall E, Giralt S, Champlin RE. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 13(4):469-77, 2007. e-Pub 2007. PMID: 17382253.
39. Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, Oran B, Sanchorawala V. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 108(12):3945-7, 2006. e-Pub 2006. PMID: 16926284.
40. Lee HJ, Oran B, Saliba RM, Couriel DM, Shin K, Massey P, Neumann J, de Lima M, Champlin R, Giralt S. Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant 38(4):299-303, 2006. e-Pub 2006. PMID: 16819437.
41. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, La Valley M, Skinner M, Seldin DC. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 35(6):567-75, 2005. PMID: 15665842.
42. Erman M, Abali H, Oran B, Haznedaroglu IC, Canpinar H, Kirazli S, Celik I. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?. Ann Oncol 15(11):1622-6, 2004. PMID: 15520062.
43. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost 92(4):747-51, 2004. PMID: 15467905.
44. Oran B, Celik I, Erman M, Baltali E, Zengin N, Demirkazik F, Tezcan S. Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women: a case-control study. Med Oncol 21(1):31-40, 2004. PMID: 15034211.
45. Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V. Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 74(2):131-5, 2003. PMID: 14508801.
46. Cobankara V, Oran B, Ozatli D, Haznedaroglu IC, Kosar A, Buyukasik Y, Ozcebe O, Dundar S, Kirazli S. Cytokines, endothelium, and adhesive molecules in pathologic thrombopoiesis. Clin Appl Thromb Hemost 7(2):126-30, 2001. PMID: 11292190.

Invited Articles

1. Oran B, Popat U, Andersson B, Champlin R. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk 13(Supplement 2):S282-8, 2013. PMID: 24290213.
2. Oran B. Can double-cord transplants provide a more potent graft-vs-leukemia effect?. Best Pract Res Clin Haematol 25(4):479-82, 2012. e-Pub 2012. PMID: 23200545.
3. Oran B, Shpall E. Umbilical cord blood transplantation: a maturing technology. Hematology Am Soc Hematol Educ Program 2012:215-22, 2012. PMID: 23233584.
4. Oran B, de Lima M. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation. Curr Opin Hematol 18(6):388-94, 2011. PMID: 21897227.
5. Oran B, Weisdorf DJ. Allogeneic stem cell transplantation in first complete remission. Curr Opin Hematol 18(6):395-400, 2011. PMID: 21912256.

Editorials

1. Oran B, Shpall EJ. Allele-Level HLA Cord Blood Matching Matters. Blood 123(1):8-9, 2014. PMID: 24385496.

Abstracts

1. Baljevic M, Cao K, Champlin RE, Popat UR, Hosing C, Shah N, Parmar S, Rezvani K, Olson A, Shpall EJ, Oran B. Dual Donor T-Cell Chimerism Does Not Predict Poor Prognosis after Double Cord Blood Allogeneic Transplantation. Biol Blood Marrow Transplant 2015 BMT Meetings 21(2, Supplement):S157, 2015. e-Pub 2015.
2. Popat UR, Fox PS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Hosing CM, Jones R, Kebriaei P, Khouri IF, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Shah N, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Timed Sequential Busulfan Is Safe in Older Patients. Blood 2014 ASH Annual Meeting 124(21):3859, 2014.
3. Ahmed S, Shpall EJ, Gulbis A, Jones R, Martinez CS, Rondon G, Rezvani K, Oran B, Olson A, Shah N, Parmar S, Popat UR, Alousi AM, ieto Y, Hosing CM, Bashir Q, Kebriaei P, Qazilbash MH, Champlin RE, Mulanovich VE. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. Blood 2014 ASH Annual Meeting 124(21):1187, 2014.
4. Tamari R, Oran B, Hilden P, Papadopoulos EB, Kongtim P, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Young JW, Popat UR, Chen J, de Lima M, O'Reilly RJ, Giralt S, Champlin RE, Castro-Malaspina H. Allo- HSCT for Advanced Myelodysplastic Syndrome:MSKCC Vs MDACC. Blood 2014 ASH Annual Meeting 124(21):2546, 2014.
5. Oran B, Cao K, Saliba RM, Hosing CM, Popat UR, de Lima M, Carmazzi Y, Alousi A, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Champlin RE, Rezvani K, Shpall EJ. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. Blood 2014 ASH Annual Meeting 124(21):2531, 2014.
6. Khouri IF, Saliba RM, Xu-Monette ZY, Korbling M, Rondon G, Valverde R, Alousi AM, Anderlini P, Ahmed S, Ciurea SO, Fayad L, Oran B, Parmar S, Popat UR, Westin JR, Turturro F, Medeiros J, Gulbis AM, Young KH. Outcomes Following Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with Primary Mediastinal (PMBL), Germinal Center B (GCB) and Non-GCB Cell-like Diffuse Large B Cell Lymphomas (DLBCL). Blood 2014 ASH Annual Meeting 124(21):2563, 2014.
7. Cabrero M, Garcia-Manero G, Sasaki K, Daver N, Borthakur G, DiNardo CD, Cortes JE, Bohannan Z, Sukholutsky V, Ravandi F, Pierce S, Kadia TM, Pemmaraju N, Oran B, Champlin RE, Kantarjian H, Jabbour E. Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. Blood 2014 ASH Annual Meeting 124(21):4666, 2014.
8. Gaballa S, Kongtim P, Rondon G, Chen J, Popat U, Ahmed S, Hosing CM, Oran B, Kebriaei P, Parmar S, Shah N, Khouri IF, Champlin RE, Ciurea SO. Feasibility and Outcomes of Haploidentical Transplantation for Elderly Patients with Advanced Hematological Malignancies: The MD Anderson Cancer Center Experience. Blood 2014 ASH Annual Meeting 124(21):1245, 2014.
9. Oran B, Saliba RM, Andersson BS, de Lima M, Popat UR, Khouri IF, Kebriaei P, Bashir Q, Ahmed S, Shpall EJ, Champlin RE, Rondon G. Improved Progression-Free Survival with Minimal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Hematological Malignancy. Blood 2014 ASH Annual Meeting 124(21):2533, 2014.
10. William BM, de Lima M, Oran B, Champlin R, Papadopoulos EB, Giralt S, Scott BL, Hetzer J, Wang X, Laille E, Skikne BS, Craddock C. CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML). Blood 2014 ASH Annual Meeting 124(21):990, 2014.
11. Oran B, Champlin RE, Cortes JE, de Lima M, Wang X, Chen HC, Ravandi F, Ciurea SO, Kantarjian HM, Borthakur G. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation. Blood 2014 ASH Annual Meeting 124(21):2531, 2014.
12. Sandmaier B, Khaled SK Oran B, Gammon G, Trone D, Frankfurt O. Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation. Blood 2014 ASH Annual Meeting 124(21):428, 2014.
13. Ghantoji SS, Goddu S, Sreenivasula S, Shah DP, Oran B, Rezvani K, Rondon G, Shpall EJ, Chemaly RF. Characteristics and Outcome of Cytomegalovirus (CMV) Infections in 95 Cord Blood Transplant (CBT) Recipients: The MD Anderson Experience. Biol Blood Marrow Transplant 2014 BMT Tandem Meetings 20(2, Supplement):S223-S224, 2014. e-Pub 2014.
14. Khouri IF, Wei W, Valverde R, Korbling M, Turturro F, Gulbis AM, Guillermo-Pacheco M, Ahmed S, Alousi A, Oran B, Anderlini P, Ciurea SO, Hosing CM, Popat UR, Jabbour E, Champlin RE, Bassett R. Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning: A Novel Regimen Inducing Immunosuppression Without Myelosuppression. Blood 2013 ASH Annual Meeting 122(21):541, 2013.
15. Popat UR, Oran B, Hosing CM, Kebriaei P, Rezvani K, Parmar S, Shah N, Bollard CM, Molldrem JJ, Nieto Y, Andersson BS, Alousi A, Jones RB, Cooper LJN, Qazilbash MH, Bashir Q, Ahmed S, Bosque D, Chen J, McCarty J, Rondon G, Munsell M, McNiece IK, Kaur I, Yvon E, Annandale K, Olchesky S, de Lima MJ, Champlin RE, Miller L, Paradiso L, Koh L, Zweidler-McKay PA, Shpall EJ. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. Blood 2013 ASH Annual Meeting 122(21):691, 2013.
16. Ahmed S, Di Stasi A, Shpall EJ, Khouri IF, Alousi AM, Ciurea SO, Bashir Q, Qazilbash M, JOnes RB, Nieto Y, Parmar S, Kebriaei P, Shah N, Rezvani K, Hosing CM, Oran B, Andreeff M, Anderlini P, Andersson BS, Champlin RE, Popat UR. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. Blood 2013 ASH Annual Meeting 122(21):2083, 2013.
17. Oran B, Poon M, Chen J, Rondon G, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing CM, Parmar S, Qazilbash MH, Popat UR, Nieto Y, Alousi A, Jones RB, Rezvani K, de Lima M, Shpall EJ, Champlin RE, Kebriaei P. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR). Blood 2013 ASH Annual Meeting 122(21):2142, 2013.
18. Di Stasi A, Poon LM, Ferro R, Milton D, Rondon G, Wang SA, Hamdi A, Qazilbash MH, Ahmed S, Khouri I, Oran B, Hosing CM, Kebriaei P, Alousi A, Popat UR, Shpall EJ, Lee DA, Rezvani K, Champlin RE, Ciurea SO. Transplant Outcomes For Patients With AML/MDS Using Melphalan-Based Conditioning. Blood 2013 ASH Annual Meeting 122(21):2167, 2013.
19. Kongtim P, Popat UR, de Lima M, Garcia-Manero G, Jabbour EJ, Chen J, Rondon G, Abruzzo LV, Ciurea SO, Shpall EJ, Champlin RE, Oran B. MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS. Blood 2013 ASH Annual Meeting 122(21):3340, 2013.
20. Khouri IF, Saliba RM, Challagundia P, Ledesma C, Korbling M, Gulbis AM, Guillermo-Pacheco M, Ahmed S, Anderlini P, Bashir Q, Oran B, Ciurea SO, Hosing CM, Kebriaei P, Popat UR, Jabbour E, Champlin RE, Jorgensen JL. Bfr (bendamustine, fludarabine, rituximab) Vs. FCR Nonmyeloablative Allogeneic Conditioning In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Outcome Results Including Minimal Residual Disease Analysis. Blood 2013 ASH Annual Meeting 122(21):3349, 2013.
21. Nusrat M, Kazmi SM, Cornelison AM, Kebriaei P, Nieto Y, Oran B, Orlowski RZ, Parmar S, Popat UR, Shah JJ, Shah N, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood 2013 ASH Annual Meeting 122(21):3358, 2013.
22. Shetty A, Kantarjian HM, Champlin RE, Borthakur G, Badar T, Garcia-Manero G, Andersson BS, Oran B, Ciurea SO, Konopleva M, Andreeff M, Kornblau SM, Wierda WG, Pierce S, Ravandi F, Cortes JE. Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years. Blood 2013 ASH Annual Meeting 122(21):3886, 2013.
23. Pingali SR, Denai M, Di Stasi A, Kebriaei P, Popat UR, Alousi A, Anderlini P, Parmar S, Hosing CM, Andersson BS, Bashir Q, Ahmed S, Oran B, Shpall EJ, Khouri I, Konopleva M, Alatrash G, Champlin RE, Ciurea SO. Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning – Interim Results From a Phase II Clinical Trial. Blood 2013 ASH Annual Meeting 122(21):4523, 2013.
24. Ghobadi A, Hamdi A, Kongtim P, Milton D, Alousi A, Anderlini P, Ciurea SO, Oran B, Khouri I, Parmar S, Qazilbash MH, Kebriaei P, Popat UR, Rezvani K, Chemaly RF, Shpall EJ, Champlin RE, Bashir Q. The Effect Of CMV Reactivation On Relapse and Survival In Patients With AML and MDS After Allogeneic Stem Cell Transplant (allo-HCT). Blood 2013 ASH Annual Meeting 122(21):4531, 2013.
25. Oran B, Quing C, Brunstein C, Majhail N, Weisdorf D. Similar And Promising Outcomes In Older AML Patients In First Complete Remission After Reduced Intensity Conditioning With Cord Blood And Sibling Donor Transplantation. Biol Blood Marrow Transplant 2010 BMT Tandem Meetings 16(Supplement 2):S231-S232, 2010.
26. Oran B, Dolan M, Ma L, Brunstein C, Warlick E, Weisdorf DJ. Monosomal Karyotype Provides Better Prognostic Prediction After Allogeneic Stem Cell Transplantation in AML Patients. Blood 2009 ASH Annual Meeting 114(22):525, 2009.
27. Rosenzweig M, Seldin DC, Remick DG, Skinner M, Quillen K, Oran B, Finn KT, Sanchorawala V. Febrile reactions occurring with a second cycle of high dose melphalan and SCT in patients with AL amyloidosis: a ‘melphalan recall’ reaction. Blood 2008 ASH Annual Meeting 112(11):1120, 2008.
28. van Besien K, de Lima M, Artz A, Oran B, Stock W, Giralt S. Alemtuzumab Reduces Chronic Graft Versus Host Disease (cGVHD) and Treatment Related Mortality (TRM) after Reduced Intensity Conditioning for AML and MDS. Blood 2007 ASH Annual Meeting 110(11):1076, 2007.
29. Seldin DC, Skinner M, Oran B, Quillen K, Finn KT, Sanchorawala V.. Relapse Rate and Long-Term Survival of AL Amyloidosis Patients Treated with High-Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT). Blood 2006 ASH Annual Meeting 108(11):3094, 2006.
30. Oran B, Hun L, de Lima M, Couriel D, MD, Giralt S , Saliba R.. Steroid complications in patiensts with acute graft versus host disease. Blood 2005 ASH Annual Meeting 106(11):5338, 2005.
31. Oran B, Aleman A, Shpall EJ, Hosing C, Korbling M, Anderlini P, Champlin R, Donato M.. Higher Rate of Thrombotic Thrombocytopenic Pupura (TTP) Associated with Graft Versus Host Disease (GVHD) and Unrelated Donor Bone Marrow Transplantation (BMT). Blood 2005 ASH Annual Meeting 106(11):1111, 2005.
32. Oran B, Saliba R, Giralt G, Couriel D, Carrasco-Yalan A, Hosing C, Shahjahan M, de Meis E, Anagnostopoulos A, Anderlini P, Ghosh S, Khouri I,. Champlin R, de Lima M.. Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Fludarabine and Melphalan (FM) Reduced Intensity Conditioning (RIC) for High-Risk AML/MDS. Blood 2005 ASH Annual Meeting 106(11):838, 2005.
33. Oran B, Giralt S, Shahjahan M, Anagnostopoulos A, Couriel D, Kebriaei P, Hosing C, Ghosh S, D Meis E, Donato M, Ativivas T, Carrasco-Yalan A, Champlin R, de Lima M.. Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens. Blood 2005 ASH Annual Meeting 106(11):2019, 2005.

Book Chapters

1. Mehta R, Oran B, Shpall E. Alternative Donor Transplant: Cord Blood Transplant. In: The M.D. Anderson Manual of Medical Oncology, 3rd Edition. McGraw Hill, 2015.